Cargando…

Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout

BACKGROUND: Topiroxostat, a selective xanthine oxidase inhibitor, shows effective reduction in the serum urate level in hyperuricemic patients with or without gout. The objective of this study was to evaluate the efficacy and safety of topiroxostat in hyperuricemic stage 3 chronic kidney disease pat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hosoya, Tatsuo, Ohno, Iwao, Nomura, Shinsuke, Hisatome, Ichiro, Uchida, Shunya, Fujimori, Shin, Yamamoto, Tetsuya, Hara, Shigeko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Japan 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4271138/ https://www.ncbi.nlm.nih.gov/pubmed/24448692 http://dx.doi.org/10.1007/s10157-014-0935-8

Ejemplares similares

Multicenter, Open-Label Study of Long-Term Topiroxostat (FYX-051) Administration in Japanese Hyperuricemic Patients with or Without Gout
por: Hosoya, Tatsuo, et al.
Publicado: (2018)

Clinical efficacy and safety of topiroxostat in Japanese hyperuricemic patients with or without gout: a randomized, double-blinded, controlled phase 2b study
por: Hosoya, Tatsuo, et al.
Publicado: (2016)

A non-inferiority study of the novel selective urate reabsorption inhibitor dotinurad versus febuxostat in hyperuricemic patients with or without gout
por: Hosoya, Tatsuo, et al.
Publicado: (2020)

Total saponins from Discorea nipponica makino ameliorate urate excretion in hyperuricemic rats
por: Zhou, Qi, et al.
Publicado: (2015)

Open-label study of long-term administration of dotinurad in Japanese hyperuricemic patients with or without gout
por: Hosoya, Tatsuo, et al.
Publicado: (2019)

Production Inhibition and Excretion Promotion of Urate by Fucoidan from Laminaria japonica in Adenine-Induced Hyperuricemic Mice
por: Zhang, Dayan, et al.
Publicado: (2018)

Randomized control trial for the assessment of the anti-albuminuric effects of topiroxostat in hyperuricemic patients with diabetic nephropathy (the ETUDE study)
por: Kato, Sawako, et al.
Publicado: (2016)

Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: randomized, multicenter, double-blind, placebo-controlled, parallel-group, confirmatory phase 2 study
por: Hosoya, Tatsuo, et al.
Publicado: (2019)

Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: an exploratory, randomized, multicenter, double-blind, placebo-controlled, parallel-group early phase 2 study
por: Hosoya, Tatsuo, et al.
Publicado: (2019)

Long-Term Safety and Effectiveness of the Xanthine Oxidoreductase Inhibitor, Topiroxostat in Japanese Hyperuricemic Patients with or Without Gout: A 54-week Open-label, Multicenter, Post-marketing Observational Study
por: Ishikawa, Tomohiko, et al.
Publicado: (2020)

Clinical Effects of Topiroxostat on Renal and Endothelial Function in A Patient with Chronic Kidney Disease and Hyperuricemic Arteriolopathy: A Case Report
por: Tanaka, Atsushi, et al.
Publicado: (2017)

Comparative effects of topiroxostat and febuxostat on arterial properties in hypertensive patients with hyperuricemia
por: Kario, Kazuomi, et al.
Publicado: (2021)

Dotinurad versus benzbromarone in Japanese hyperuricemic patient with or without gout: a randomized, double-blind, parallel-group, phase 3 study
por: Hosoya, Tatsuo, et al.
Publicado: (2020)

Renoprotective effect of topiroxostat via antioxidant activity in puromycin aminonucleoside nephrosis rats
por: Kawamorita, Yosuke, et al.
Publicado: (2017)

Effect of Urate-Lowering Therapy on All-Cause and Cardiovascular Mortality in Hyperuricemic Patients without Gout: A Case-Matched Cohort Study
por: Chen, Jiunn-Horng, et al.
Publicado: (2015)

Gypenosides Inhibits Xanthine Oxidoreductase and Ameliorates Urate Excretion in Hyperuricemic Rats Induced by High Cholesterol and High Fat Food (Lipid Emulsion)
por: Pang, Minxia, et al.
Publicado: (2017)

Hypouricemia and Urate Transporters
por: Otani, Naoyuki, et al.
Publicado: (2022)

The Effects of Topiroxostat, a Selective Xanthine Oxidoreductase Inhibitor, on Arterial Stiffness in Hyperuricemic Patients with Liver Dysfunction: A Sub-Analysis of the BEYOND-UA Study
por: Fujishima, Yuya, et al.
Publicado: (2023)

Dendrobium officinalis Six Nostrum Promotes Intestinal Urate Underexcretion via Regulations of Urate Transporter Proteins in Hyperuricemic Rats
por: Ge, Hongzhang, et al.
Publicado: (2023)

Urate in fingernail represents the deposition of urate burden in gout patients
por: Chen, Haibing, et al.
Publicado: (2020)

Decreased extra-renal urate excretion is a common cause of hyperuricemia
por: Ichida, Kimiyoshi, et al.
Publicado: (2012)

Urate crystal deposition in hyperuricemic children: a dual energy computed tomography study
por: Ying, Qianqian, et al.
Publicado: (2021)

The ABCG2 Q141K hyperuricemia and gout associated variant illuminates the physiology of human urate excretion
por: Hoque, Kazi Mirajul, et al.
Publicado: (2020)

Variation in serum urate levels in the absence of gout and urate lowering therapy
por: Shaffer, Andrew, et al.
Publicado: (2021)

The effect for hyperuricemia inpatient of uric acid overproduction type or in combination with topiroxostat on the pharmacokinetics, pharmacodynamics and safety of dotinurad, a selective urate reabsorption inhibitor
por: Okui, Daisuke, et al.
Publicado: (2019)

Renoprotective Effect of Xanthine Oxidase Inhibitor, Topiroxostat
por: Katsuyama, Hisayuki, et al.
Publicado: (2019)

Anti-Hyperuricemic Effects of Astaxanthin by Regulating Xanthine Oxidase, Adenosine Deaminase and Urate Transporters in Rats
por: Le, Yanzuo, et al.
Publicado: (2020)

Podocyte Injury and Albuminuria in Experimental Hyperuricemic Model Rats
por: Asakawa, Shinichiro, et al.
Publicado: (2017)

Anti-hyperuricemic and Anti-inflammatory Effects of Marantodes pumilum as Potential Treatment for Gout
por: Rahmi, Eldiza Puji, et al.
Publicado: (2020)

Adherence with urate-lowering therapies for the treatment of gout
por: Harrold, Leslie R, et al.
Publicado: (2009)

Systemic Urate Deposition: An Unrecognized Complication of Gout?
por: Khanna, Puja, et al.
Publicado: (2020)

Urate‐lowering therapy for patients with gout on hemodialysis
por: Alkilany, Reem, et al.
Publicado: (2022)

Is urate crystal precipitation a predictor of cardiovascular risk in hyperuricemic patients? A Danish cohort study
por: Larsen, Kasper Søltoft, et al.
Publicado: (2015)

Effects of ChondroT on potassium Oxonate-induced Hyperuricemic mice: downregulation of xanthine oxidase and urate transporter 1
por: Oh, Dool-Ri, et al.
Publicado: (2019)

TGF-β is elevated in hyperuricemic individuals and mediates urate-induced hyperinflammatory phenotype in human mononuclear cells
por: Klück, Viola, et al.
Publicado: (2023)

Hyperuricemia in acute gastroenteritis is caused by decreased urate excretion via ABCG2
por: Matsuo, Hirotaka, et al.
Publicado: (2016)

The relationship between ferritin and urate levels and risk of gout
por: Fatima, Tahzeeb, et al.
Publicado: (2018)

Coevolution of URAT1 and Uricase during Primate Evolution: Implications for Serum Urate Homeostasis and Gout
por: Tan, Philip K., et al.
Publicado: (2016)

The effect of febuxostat to prevent a further reduction in renal function of patients with hyperuricemia who have never had gout and are complicated by chronic kidney disease stage 3: study protocol for a multicenter randomized controlled study
por: Hosoya, Tatsuo, et al.
Publicado: (2014)

Cordycepin, a Characteristic Bioactive Constituent in Cordyceps militaris, Ameliorates Hyperuricemia through URAT1 in Hyperuricemic Mice
por: Yong, Tianqiao, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_kr6i6hq1t3fuv08nbarucjon5e